Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate and compare major pathological
response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus
platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab
as adjuvant treatment versus participants receiving placebo plus platinum-based doublet
chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.